Quoin Pharmaceuticals (QNRX) Change in Accured Expenses (2021 - 2026)

Quoin Pharmaceuticals has reported Change in Accured Expenses for 6 years, with the latest figure at -$200904.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 129.78% year-over-year to -$200904.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $449545.0 (up 45.88% YoY) and the FY2025 annual result came in at $1.3 million, up 380.2% from the prior year.
• Change in Accured Expenses grew to -$200904.0 in Q1 2026 per QNRX's latest filing, from -$258491.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.4 million in Q3 2025 and troughed at -$998948.0 in Q4 2023.
• A 5-year average of $72723.4 and a median of $162133.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 1341.21% in 2023, then soared 398.04% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$69313.0 in 2022, then sank by 1341.21% to -$998948.0 in 2023, then soared by 138.41% to $383696.0 in 2024, then tumbled by 167.37% to -$258491.0 in 2025, then climbed by 22.28% to -$200904.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$200904.0, -$258491.0, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.